Cytokinetics | CYTK - Selling And Administration Expenses


Cytokinetics reported $113.14M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.88M 1.69M Sep/2026
Amgen USD 1.68B 40M Sep/2026
Arca Biopharma USD 2.23M 1.08M Dec/2025
Bayer EUR 4.02B 53M Sep/2026
Biogen USD 752M 42.3M Sep/2026
Brainstorm Cell Therapeutics USD 1.21M 178K Mar/2026
Bristol-Myers Squibb USD 1.7B 127M Sep/2026
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Cytokinetics USD 113.14M 8.75M Sep/2026
Eisai JPY 120.4B 5.58B Sep/2026
Eli Lilly USD 3.12B 305M Sep/2026
Exelixis USD 154.56M 6.93M Sep/2026
Geron USD 35.7M 3.16M Sep/2026
Halozyme Therapeutics USD 58.24M 1.24M Sep/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
Ligand Pharmaceuticals USD 72.62M 43.49M Sep/2026
Merck USD 2.86B 25M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Pfizer USD 3.28B 132M Sep/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026